Stress and host immunity amplify Mycobacterium tuberculosis phenotypic heterogeneity and induce nongrowing metabolically active forms

Cell Host Microbe. 2015 Jan 14;17(1):32-46. doi: 10.1016/j.chom.2014.11.016. Epub 2014 Dec 24.

Abstract

Nonreplicating and metabolically quiescent bacteria are implicated in latent tuberculosis infections and relapses following "sterilizing" chemotherapy. However, evidence linking bacterial dormancy and persistence in vivo is largely inconclusive. Here we measure the single-cell dynamics of Mycobacterium tuberculosis replication and ribosomal activity using quantitative time-lapse microscopy and a reporter of ribosomal RNA gene expression. Single-cell dynamics exhibit heterogeneity under standard growth conditions, which is amplified by stressful conditions such as nutrient limitation, stationary phase, intracellular replication, and growth in mouse lungs. Additionally, the lungs of chronically infected mice harbor a subpopulation of nongrowing but metabolically active bacteria, which are absent in mice lacking interferon-γ, a cytokine essential for antituberculosis immunity. These cryptic bacterial forms are prominent in mice treated with the antituberculosis drug isoniazid, suggesting a role in postchemotherapeutic relapses. Thus, amplification of bacterial phenotypic heterogeneity in response to host immunity and drug pressure may contribute to tuberculosis persistence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antitubercular Agents / therapeutic use
  • Disease Models, Animal
  • Female
  • Gene Expression Profiling
  • Host-Pathogen Interactions*
  • Isoniazid / therapeutic use
  • Lung / microbiology
  • Mice, Inbred C57BL
  • Microscopy
  • Mycobacterium tuberculosis / growth & development
  • Mycobacterium tuberculosis / immunology*
  • Mycobacterium tuberculosis / metabolism
  • Mycobacterium tuberculosis / physiology*
  • Ribosomes / genetics
  • Single-Cell Analysis
  • Stress, Physiological*
  • Time-Lapse Imaging
  • Tuberculosis / drug therapy
  • Tuberculosis / microbiology*

Substances

  • Antitubercular Agents
  • Isoniazid